This site is intended for healthcare professionals

Pivotal trial of OMS 721 shows efficacy in HSCT-TMA.- Omeros Corp

Read time: 1 mins
Last updated:26th Oct 2020
Published:23rd Oct 2020
Omeros Corporation announced final data from its pivotal trial for OMS 721 (narsoplimab) in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell transplantation for which there is no approved therapy.
Condition: Thrombotic Microangiopathies /HSCT- TMA
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest